Want help reviewing this study?
Study ID: NCT07286175. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT07286175
A Study of Brenipatide in Adult Participants With Bipolarity (RENEW-Bipolar-1)
This study evaluates the safety and effectiveness of Brenipatide for people with bipolarity.
Medication studyAges 18–75Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Brenipatide for people with bipolarity.
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
- Listed locations
- Orange, United States · New Haven, United States and 74 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Registry last updated: · Record retrieved: . These dates do not confirm site availability.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 24, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 400
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Argentina, Brazil, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07286175
- Official title
- A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Recruitment & locations
RecruitingOrange, United States · New Haven, United States · Hialeah, United States
73 more locations
- Maitland, United States
- Miami Lakes, United States
- Naples, United States
- Orlando, United States
- Weston, United States
- Atlanta, United States
- Waterloo, United States
- Gaithersburg, United States
- Springfield, United States
- Watertown, United States
- Philadelphia, United States
- McKinney, United States
- Richardson, United States
- Clinton, United States
- Fairfax, United States
- Bellevue, United States
- ABB, Argentina
- Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- Santiago del Estero, Argentina
- Brasília, Brazil
- Campinas, Brazil
- Marília, Brazil
- Rio de Janeiro, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- Valinhos, Brazil
- Changsha, China
- Hangzhou, China
- Huzhou, China
- Jinan, China
- Shanghai, China
- Shijiazhuang, China
- Tianjin, China
- Xiamen, China
- Zhumadian, China
- Aurangabad, India
- Belgavi, India
- Bhopal, India
- Chhatrapati Sambhajinagar, India
- Dehradun, India
- Dharwad, India
- Lucknow, India
- Mysore, India
- Nashik, India
- Pune, India
- Tiruchirappalli, India
- Varanasi, India
- Chikugo, Japan
- Chiyoda City, Japan
- Fukushima, Japan
- Iruma, Japan
- Karatsu, Japan
- Kōtō City, Japan
- Kumamoto, Japan
- Kure, Japan
- Kurume, Japan
- Sagamihara, Japan
- Shibuya-ku, Japan
- Tokyo, Japan
- Toshima City, Japan
- Yamagata, Japan
- Yokohama, Japan
- Chihuahua City, Mexico
- Guadalajara, Mexico
- Mazatlán, Mexico
- Mexico City, Mexico
- Mérida, Mexico
- Morelia, Mexico
- Bayamón, Puerto Rico
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Brenipatide for people with bipolarity.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Does this study involve medication?
Yes. The study involves medication, including Brenipatide and Placebo.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT06696755
Adverse Events and Change for Bipolarity
The registry lists this study as recruiting. Study locations are listed in the United States. Confirm recruitment at each site. It is testing adverse Events and Change for Bipolarity.
RecruitingNCT04777357
Change for depression
The registry lists this study as recruiting. Study locations are listed in the United States and in Russia. Confirm recruitment at each site. It is testing change for depression.
RecruitingNCT06929273
KarXT for manic episodes in bipolarity type I
The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in France, ... Confirm recruitment at each site. It is testing KarXT for manic episodes in bipolarity type I.